Samuel Bates Martin - 23 Dec 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP and CFO
Signature
/s/ Anthony S. Marucci, attorney in fact for Samuel Bates Martin
Issuer symbol
CLDX
Transactions as of
23 Dec 2021
Net transactions value
-$359,271
Form type
4
Filing time
28 Dec 2021, 15:02:42 UTC
Previous filing
17 Nov 2021
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $29,304 +3,250 +12% $9.02 30,128 23 Dec 2021 Direct
transaction CLDX Common Stock Options Exercise $10,425 +3,750 +12% $2.78* 33,878 23 Dec 2021 Direct
transaction CLDX Common Stock Sale $399,000 -9,500 -28% $42.00 24,378 23 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -3,250 -25% $0.000000 9,530 23 Dec 2021 Common Stock 3,250 $9.02 Direct F2
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -3,750 -13% $0.000000 24,421 23 Dec 2021 Common Stock 3,750 $2.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.
F2 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F3 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.